•  •  Dark Mode

Your Interests & Preferences

I am a...

law firm lawyer
in-house company lawyer
litigation lawyer
law student
aspiring student

Website Look & Feel

 •  •  Dark Mode
Blog Layout

Save preferences

Khaitan, Amarchand, AZB, Herbies on $193m Otsuka,Mitsui-Claris pharma JV

Indo-Jap $193m injectables JV
Indo-Jap $193m injectables JV
Khaitan & Co, with Herbert Smith Freehills, advised the Japanese Otsuka Pharmaceutical Factory (OPF), in co-investing Rs 1050 crore ($193m) in Indian pharma company Claris Lifesciences, to form a joint venture (JV). Claris was advised by AZB & Partners. Japan’s Mitsui & Co, advised by Amarchand Mangladas, was the other investor.

Khaitan & Co Mumbai corporate partner Bhavik Narsana led the transaction with inputs on specific issues from corporate partner Rabindra Jhunjhunwala, banking partner Devidas Banerji, litigation partner Chakrapani Misra, partners Sudip Mullick and Abhishek Sharma on real estate, with competition law counsel Avaantika Kakkar, tax executive directors Daksha Baxi and Dinesh Agarwal and principal associate Adheesh Nargolkar, in acting for OPF which is Japanese diversified healthcare group Otsuka’s originating company.

Herbert Smith Freehills Tokyo partner James Robinson also acted for OPF.

AZB & Partners Mumbai partner Abhijit Joshi with associates Nilanjana Singh and Adarsh Varghese acted for the Ahmedabad-based Claris Lifesciences which is India’s largest injectable drugs maker and which entered into the JV through its subsidiary Claris Specialty Injectibles.

Amarchand Mangaldas Delhi partner Amit Kumar with principal associate Saurav Kumar and senior associate Ambarish acted for Mitsui & Co which is Japan’s largest general trading company.

Claris Lifesciences and Mitsui & Co will hold 20 per cent each, while OPF will hold 60 per cent in the JV Claris Specialty Injectibles, according to the Economic Times.

The JV will help introduce Otsuka’s products for the first time to the Indian drugs market, according to DNA India.

Photo credits: Ein86

Click to show 7 comments
at your own risk
By reading the comments you agree that they are the (often anonymous) personal views and opinions of readers, which may be biased and unreliable, and for which Legally India therefore has no liability. If you believe a comment is inappropriate, please click 'Report to LI' below the comment and we will review it as soon as practicable.